13. The pharmaceutical composition of claim 12, wherein the second anti-respiratory syncytial virus agent is selected from the group consist of RSV-IGIV, palivizumab, motavizumab, MK-1654, I-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one (BMS-43377...